

RESEARCH ARTICLE

LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells

Tao Zeng¹✉, Dan Wang¹✉, Juan Chen¹✉, Yuanyuan Tian², Xuefei Cai¹, Hong Peng¹, Liying Zhu¹, Ailong Huang^{1,3*}, Hua Tang^{1*}

1 Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China, **2** Qingdao Women and Children Hospital, Qingdao, China, **3** Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, China

✉ These authors contributed equally to this work.

* tanhua86162003@cqmu.edu.cn (HT); ahuang1964@163.com (AH)



OPEN ACCESS

Citation: Zeng T, Wang D, Chen J, Tian Y, Cai X, Peng H, et al. (2017) LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. PLoS ONE 12(5): e0177843. <https://doi.org/10.1371/journal.pone.0177843>

Editor: Aamir Ahmad, University of South Alabama Mitchell Cancer Institute, UNITED STATES

Received: February 2, 2017

Accepted: May 4, 2017

Published: May 19, 2017

Copyright: © 2017 Zeng et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The Major National S&T Program (2013ZX10002002, ALH), the major project of Chongqing Science & Technology Commission (cstc2013jcyjC10002, ALH), the Natural Science Foundation Project of CQ CSTC (2010BB5359, ALH), the Nature Science Foundation of China (81471946, ALH).

Abstract

Long non-coding RNAs (lncRNAs), tentatively identified as non-protein coding RNA, are transcripts more than 200nt in length and accounting for 98% of the whole genome of human being. Accumulating evidence showed aberrant expressions of lncRNAs are strongly correlated to the development of cancers. In this study, AF113014 is a new lncRNA identified from Microarray. We found AF113014 is differentially expressed between HCC cell lines and normal hepatocytes. Functionally, AF113014 inhibited proliferation of HCC cells both *in vitro* and *in vivo*, whereas the opposite effect was observed when AF113014 knockdown. Moreover, we identified that Egr2, a tumor suppressor gene, was a downstream target gene of AF113014. Furthermore, we discovered that AF113014 up-regulated Egr2 expression through interacting with miR-20a by using dual-luciferase reporter assay, qRT-PCR and Western blotting analysis. Our data provides a new insight for understanding the mechanisms of HCC.

Introduction

Hepatocellular carcinoma (HCC), the third cause of death, is one of the most common malignant tumors worldwide. Although the medical technology of diagnosis and treatment has been improved yearly, the mortality of HCC is still growing [1, 2]. Biomarkers not only help to diagnose the early stages of tumors rapidly, but also to implement effective individualized treatment and to assess the prognosis of patients [3–5]. However, the current research on HCC related biomarkers is still limited. It is important to find novel therapeutic targets for more accurate diagnosis and effective treatments.

In recent years, researchers found that only 2% of the whole genome of human being are protein coding genes, and the rest 98% are transcribed to non-coding RNAs (ncRNAs). Among them, long non-coding RNA (lncRNA) is of great interest as it could regulate and control the activity of protein coding gene directly or indirectly [6–9]. lncRNAs, tentatively identified as

Competing interests: The authors have declared that no competing interests exist.

non-protein coding RNA, transcripts more than 200nt in length and accounting for about 80% of the ncRNA, usually have polyA tail structure [10].

Previously, lncRNA was considered as “junk gene” of none biological function and by-products transcribed from RNA polymerase II. Now, lncRNA not only participates in normal physiological activity of cells, but also closely relates to the pathological mechanism, disease development and prognosis of many tumors possibly through ways such as chromosome modification, cutting and splicing, transcriptional activation, mRNA degradation and translational control [11–15]. For example, H19 is a maternal characterization of non-coding RNA with the biphasic effect of tumor promoter and suppressor. H19 suppressed metastasis in HCC through activating miR-200 family. H19 also could be activated by c-MYC in breast cancer and down-regulated by p53 in hepatocellular carcinoma. In contrast, H19 locus clearly displays a tumor suppressor effect in mice [16–18]. lncRNA-HEIH, as a proto-oncogene, is significantly associated with tumor recurrence and prognosis in HBV related-HCC [19]. HOTAIR increased cancer invasiveness and metastasis dependent on PRC2 [20]. Although there are increasing researches on lncRNAs, few of these functional mechanisms have clear understanding. At present, the mechanism of lncRNA function mainly through the following ways: lncRNA combines with specific protein partners to influence their activity and localization; lncRNA competitively combines with miRNA to regulate its target mRNA; lncRNA may have an enhancer effect on certain coding genes; lncRNA can also affect the expression of its neighboring genes, in other words, by changing its physical location to the target genes [21–24].

Recently, Braconi *et al.* [25] showed that AF113014 was differentially expressed between HCC cell lines and the normal hepatocytes based on microarray analysis. AF113014 is a newly identified lncRNA whose role in the development of cancer has not been reported yet. In this study, we detected the expression and function of AF113014 in tumor growth *in vitro* and *in vivo*. Our study further found that AF113014 can up-regulate anti-oncogene Egr2 expression by interaction with miR-20a. We explained how AF113014 could inhibit proliferation of hepatocellular carcinoma cells. Our work provided a new perspective in comprehending the connection between lncRNA and HCC, and suggested that AF113014 was a tumor suppressor in HCC and might be a novel potential target for therapy of HCC.

Materials and methods

Cell lines

Human immortalized normal hepatocytes (L02) and human HCC lines SMMC7721, HepG2, SK-Hep1 and Huh7 were preserved in our lab and cultured in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, China), supplemented with 10% fetal bovine serum (Gibco, USA), 100U/ml penicillin and 100ug/ml streptomycin. Cells were maintained in a humidified incubator with 5% CO₂ at 37°C.

RNA extraction and quantitative real-time PCR (qRT-PCR)

Total RNAs from cell lines were extracted with TRIzol reagent (Invitrogen, CA) and the first-strand cDNA was generated using the PrimeScript RT reagent kit with gDNA Eraser (Takara, Japan) or miRNA cDNA Kit (CWBio, China) according to the manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using UltraSYBR mixture (Cwbio, China) and conducted using the CFX Connet TM real-time PCR system (Bio-Rad, USA). The quantification analysis was analyzed by the $2^{-\Delta\Delta CT}$ method [26]. GAPDH and U6 mRNA were used for normalization. All the primers are listed in Table 1.

Table 1. Primer sequences used for PCR or plasmids construction and siRNA sequence.

Real-time PCR primer	Sequence (5'-3')
GAPDH-F	CGACCACTTTGTCAAGCTCA
GAPDH-R	AGGGGTCTACATGGCAACTG
AF113014-F	TCCAGTCATTGCTAAGTGTC
AF113014-R	ATCAGGCAGGTCTGGAAAATAG
Egr2-F	GCCGTAGACAAAATCCCAG
Egr2-R	CCACTCCGTTTCATCTGGTC
miR-20a	TAAAGTGCTTATAGTGCAGGTAG
snRNA U6-F	AGAGCCTGTGGTGTC
snRNA U6-R	CATCTTCAAAGCACTTCCCT
AF113014 over-expression primer	Sequence (5'-3')
Ad-AF113014-F	CGGGATCCGATGCCTCTACCTATCAGATGTTG
Ad-AF113014-R	CCAAGCTTTGGGCCACATTTTACTCTTGTC
pGL3-control-Egr2-3'UTR-F	AGCTCTAGATTGACTAGGTTTTGCTAC
pGL3-control-Egr2-3'UTR-R	AGCTCTAGAAGTATGCTCTGATTG
siRNA sequences	Sequence (5'-3')
siRNA NC	UUCUCCGACGUGUCACGUTT ACGUGACACGUUCGGAGAATT
siAF113014	CCUUAACUCCCUCAGUUAUTT AUAACUGAGGGAGUUAAGGTT
siEgr2	CUCUCUACAAUCCGUAACUdTdT AGUUACGGAUUGUAGAGAGdTdT

<https://doi.org/10.1371/journal.pone.0177843.t001>

Vector construction and transfection

All sequences of cloning primers are shown in Table 1. The full-length AF113014 was PCR-amplified from the genomic DNA of L02 cells and cloned into *Bam*H I and *Hind* III sites of pAdTrace-TO4 shuttle vector (preserved in our lab). CDS region of Egr2 was cloned into *Bam*H I and *Hind* III sites of pAdTrace-TO4 shuttle vector. After generating recombinant adenoviruses in HEK-293 packaging cells, we got virus lysate named Ad-AF113014 and Ad-Egr2, which could over-expression AF113014 and Egr2. The relative negative control adenovirus (Ad-GFP) was preserved in our lab. In the present study, adenovirus infection efficiency is nearly to 100% (S1 Fig). The 3'-UTR of human EGR2 containing miR-20a binding site was PCR-amplified and cloned into the *Xba* I site of pGL3-control dual-luciferase miRNA target expression vector (Promega, USA). siAF113014, siEgr2 and its negative control (siRNA NC) were purchased from Invitrogen (Shanghai, China), their sequences are listed in Table 1. Cells were transfected with a Lipofectamine 2000 kit (Invitrogen, CA) according to the manufacturer's instructions. All constructed vectors were confirmed by DNA sequencing.

MTS assay

The mock and infected cells (3,900 cells/well) were seeded into 96-well plates after 24h transfection. Three wells of each group were detected at different time points (12, 24, 48, and 72h) using the MTS kit (Promega, USA), followed the manufacturer's protocol. Then the absorbance was measured at 490nm. All experiments were repeated 3 times.

Colony formation assay

The mock and infected cells (1×10^5 cells/well) were seeded into 6-well plates after 24h transfection and cultured for 7 days. Clones were fixed with 4% paraformaldehyde for 30 min and

stained with a crystal violet cell colony staining kit (GenMed Scientifics, USA) according to the manufacturer's instructions.

Western blot analysis

Total protein was extracted from tissues or cells using RIPA buffer (Beyotime, China), supplementing with 1 mmol/L PMSF. Then the protein concentration was measured by the BCA Assay Kit (Beyotime, China). 50 µg of proteins were separated by 10% SDS-PAGE and transferred to a PVDF membrane. Proteins were probed with Egr2 primary antibody (Cat # 13491-1-AP, 1:750, Proteintech) and GAPDH (Cat # 10494-1-AP, 1:5000, Proteintech), respectively. The blots were incubated with a goat anti-rabbit HRP secondary antibody (Cat #SA00001-2, 1:5000, Proteintech). Finally, the integrated density of the band was detected using an ECL Detection Reagent (Millipore, MA) and quantified by Image Lab software (Bio-Rad, USA).

Luciferase reporter gene assays

SMMC7721 cells were seeded into 24-well plates at a density of 50% and allowed to settle for 12h. Cells were co-transfected with Ad-AF113014 or Ad-GFP, 300ng pTARGET-miR-20a or pTARGET vector (both preserved in our lab), 200ng pGL3-control-Egr2-3'UTR or pGL3-control and 25ng of the control Renilla plasmid pRL-TK (Promega, USA) using Lipofectamine2000. Luciferase and renilla signals were measured 48h after transfection using the Dual-Luciferase Reporter Assay System (Promega, USA). All experiments were performed in triplicate and repeated 3 times.

Tumor xenograft implantation in nude mice

Four-week-old female BALB/C nude mice were purchased from the Laboratory Animal Services Center of Chongqing Medical University (Chongqing, China). Animal handling and experimental procedures were approved by the Animal Experimental Ethics Committee of Chongqing Medical University. The mice were divided into two groups randomly: control group (Ad-GFP), AF-113014 group (Ad-AF113014). Adenovirus infected SMMC7721 cells respectively for 48h before cells were collected. 1×10^6 cells were subcutaneously injected in the hip back of nude mice. Tumor volume was measured every five days and calculated using the equation: $\text{volume (mm}^3\text{)} = \text{length} \times \text{width}^2 / 2$. 4 weeks later, mice were sacrificed and tumors were dissected.

Immunohistochemistry

Paraformaldehyde-fixed, paraffin-embedded tissues of transplanted tumors were sectioned at 4.5µm thickness. They were detected by an antibody Ki-67 (BS1454, 1:100, Bioworld) and Egr2 (Cat#13491-1-AP, 1:50, Proteintech), as well as the slides of cells. Visualization was achieved using 3, 3'-diaminobenzidine substrate and sections stained with PBS were regarded as the negative staining control.

Human tissue samples

Human liver cancer tissues and paired pericarcinomatous tissues were collected from the 1st or 2nd Affiliated Hospitals of Chongqing Medical University between 2010 and 2012. The tissues were from patients who had surgery for HCC without radiotherapy and chemotherapy. The human subject protocol was approved by the Clinical Research Ethics Committee of Chongqing Medical University. Written consent was obtained from each patient.

Statistical analysis

Data are expressed as the means and standard deviations. Statistical analysis was performed by χ^2 analysis and Student's t test. $P < 0.05$ was considered statistically significant.

Results

Expression of AF113014 was down-regulated in HCC cell lines

We firstly identified whether AF113014 was a lncRNA. DNAsist software analysis showed that AF113014 cannot code successive amino acids and software (http://cpc.cbi.pku.edu.cn/programs/run_cpc.jsp) also predicted AF113014 has non-coding capacity. Then we examined the AF113014 expressions in normal liver cell (L02) and a panel of HCC cell lines (SMMC7721, HepG2, SK-Hep1, Huh7) by qRT-PCR. The results showed that AF113014 were significantly lower in the HCC cell lines, compared with L02 (Fig 1).

AF113014 inhibited proliferation of HCC cell *in vitro*

Next, we sought to evaluate the biological functions of AF113014. Over-expression by adenovirus or suppression by siRNA was used to identify the functional role of AF113014 on tumor growth in SMMC7721 cells and Huh-7 cells by MTS and colony formation assay. The over-expressing or knockdown efficiency in SMMC7721 cells and Huh-7 cells were verified by qRT-PCR (Fig 2A). MTS and colony formation assay showed that AF113014 over-expression significantly reduced HCC cells proliferation, whereas AF113014 knockdown promoted cell




Fig 1. Expressions of AF113014 were down-regulated in HCC cell lines. lncRNA-AF113014 expressions in L02 and HCC cell lines. * $P < 0.05$ vs L02.

<https://doi.org/10.1371/journal.pone.0177843.g001>




Fig 2. AF113014 inhibited proliferation of HCC cells *in vitro*. (A) Relative expressions of AF113014 in SMMC7721 and Huh-7 cells transfected with Ad-AF113014 or siAF113014. GAPDH was used as reference gene in real-time PCR. (B) Proliferations of SMMC7721 and Huh-7 cells transfected with Ad-AF113014 or siAF113014 were examined by MTS. (C) Proliferations of SMMC7721 and Huh-7 cells transfected with Ad-AF113014 or siAF113014 were examined by colony formation assay. *P<0.05, **P<0.01.

<https://doi.org/10.1371/journal.pone.0177843.g002>

proliferation (Fig 2B and 2C). Therefore, these results suggested that AF113014 could regulate cell proliferation of HCC cells.

Egr2 was a target gene of AF113014

How did AF113014 affect HCC proliferation? We found that gene NRBF2 and Egr2 were located in the upstream of AF113014 position in the chromosome through bioinformatics analysis (Fig 3A). It has reported that NRBF2 mainly involved in starvation-induced autophagy [27–29]. Overexpressed or knockdown AF113014, the expressions of NRBF2 protein were no obvious change (S2 Fig). This result meant that AF113014 had no effect on NRBF2. However, Egr2 had biological functions such as cell apoptosis, differentiation and proliferation [30–36]. Base on the above finding, we supposed that Egr2 might be a target gene of AF113014.


Next, we explored the association between AF113014 and Egr2 by qRT-PCR and western blotting analysis. Our data showed that overexpression of AF113014 increased Egr2 expression

A


Homo sapiens chromosome 10, GRCh38.p2 Primary Assembly

NCBI Reference Sequence: NC_000010.11

GenBank FASTA



B



C




Fig 3. Egr2 was downstream target gene of AF113014. (A) The location of AF113014 in chromosome 10. (B, C) Relative mRNA and protein expressions of Egr2 in Ad-AF113014 or siAF113014 transfected SMMC7721 cells, respectively. GAPDH was used as an internal quantitative control. * P < 0.05, ** P < 0.01.

<https://doi.org/10.1371/journal.pone.0177843.g003>

in SMMC7721 cells at both mRNA and protein levels. In contrast, AF113014 knockdown decreased the expressions of Egr2 (Fig 3B and 3C). Taken together, these data suggest that AF113014 could regulate Egr2 expression.

Egr2 were down-regulated in HCC cell lines

As a target gene of AF113014, what is the biological function of Egr2? Firstly, we assessed Egr2 expression in HCC cell lines by qRT-PCR (Fig 4A) and immunostaining (Fig 4B). The data showed that the expression of Egr2 were downregulated in HCC cell lines, compared with the hepatic immortal cell line L02.




Fig 4. Egr2 was down-regulated in HCC cell lines. (A) Relative expression of Egr2 in LO2 and HCC cells was analyzed by qRT-PCR. (B) Relative expression of Egr2 in LO2 and HCC cells was detected by immunohistochemistry. *P<0.05, **P<0.01.

<https://doi.org/10.1371/journal.pone.0177843.g004>

Egr2 suppressed HCC cell proliferation *in vitro*

To examine the function of Egr2 in HCC, adenovirus expressing Egr2 or siRNA targeting Egr2 was used. The efficiencies of Egr2 over-expression or knockdown in SMMC7721 cells were assessed by qRT-PCR and western blot (Fig 5A). As expected, decreased proliferation was observed when over-expressed Egr2, and increased cell proliferation was observed when Egr2 was silenced in SMMC7721 cells by MTS and colony formation assay (Fig 5B and 5C). These results showed that Egr2 could inhibit the proliferation of HCC cells.

AF113014 up-regulated Egr2 expression by interacting with miR-20a

As a target gene of AF113014, how Egr2 was regulated by AF113014? Many studies showed that lncRNAs and microRNAs could constitute regulatory networks [37–41]. To better understand the mechanism, we carried out several experiments to identify whether AF113014 could




Fig 5. Egr2 Suppressed HCC cell proliferation *in vitro*. (A) Relative mRNA and protein expressions of Egr2 in Ad-Egr2 or siEgr2 transfected SMMC7721 cells. (B) Proliferations of SMMC7721 transfected with Ad-Egr2 or siEgr2 were testified by MTS. (C) Proliferations of SMMC7721 transfected with Ad-Egr2 or siEgr2 were examined by colony formation assay. *P<0.05, **P<0.01.

<https://doi.org/10.1371/journal.pone.0177843.g005>




Fig 6. AF113014 up-regulated Egr2 expression by interacting with miR-20a. (A) Software predicted the binding sites between AF113014, miRNA-20a and Egr2-3'UTR. (B) Relative expressions of miRNA-20a in Ad-AF113014 or siAF113014 transfected SMMC7721 cells. U6 RNA was used as control. (C) Luciferase activity assay was performed to determine the relationship between AF113014, miRNA-20a and Egr2 in SMMC7721 cells. * P < 0.05, ** P < 0.01. (D) qRT-PCR were performed to analyze the expressions of Egr2 after co-transfected with Ad-AF113014 and miRNA-20a, Ad-AF113014 and miRNA-20a-in, siAF113014 and miRNA-20a, siAF113014 and miRNA-20a-in, respectively. Ad-GFP+NC was used as control. (E) Western blot were performed to analyze the expressions of Egr2 after co-transfected with Ad-AF113014 and miRNA-20a, Ad-AF113014 and miRNA-20a-in, siAF113014 and miRNA-20a, siAF113014 and miRNA-20a-in, respectively. Ad-GFP+NC was used as control.

<https://doi.org/10.1371/journal.pone.0177843.g006>

interact with some miRNAs which regulated Egr2. First of all, we screened a series of candidate miRNAs that can interact with the 3'-untranslated regions (3'-UTRs) of Egr2. miR-20a [42, 43], miR-150, miR-137, miR-224, miR-337 were identified (S3 Fig). Interestingly, we found that there was base complementary relationship between AF113014, miRNA-20a and Egr2-3'UTR (Fig 6A). qRT-PCR results showed that AF113014 overexpression could result in a significant down-regulation of miRNA-20a while knockdown of AF113014 increased miRNA-

20a expression (Fig 6B). Moreover, the relationship of lncRNA-AF113014, miRNA-20a and Egr2 was analyzed by using dual-luciferase reporter assay. Results showed that the luciferase activity of Egr2-3'UTR was lower in cells expressing miR-20a compared with its control. However, this inhibition could be partially rescued when AF113014 was overexpressed (Fig 6C). Although, the expressions of Egr2 could be downregulated by miR-20a, AF113014 could recover the inhibition of miR-20a, and increased the expressions of Egr2 in presence of miR-20a (Fig 6D and 6E). Furthermore, to explore the roles of Egr2 and miRNA-20a in the effect of AF113014 upon the cell growth, RNAi suppression of Egr2 and overexpression of miR-20a in cells transduced with AF113014 were carried out. As a result, AF113014 enhanced Egr2 functions in inhibition of cell growth and colony formation (Fig 7A and 7B). The expression




Fig 7. Proliferation functions of AF113014 effected on miR-20a and Egr2 in HCC cells. (A) Proliferations of SMMC7721 cells were examined by MTS after co-transfected with Ad-AF113014, miR-20a, miR-20a-in, Ad-Egr2, si-Egr2 in groups. (B) Proliferations of SMMC7721 cells were examined by colony formation assay after co-transfected with Ad-AF113014, miR-20a, miR-20a-in, Ad-Egr2, si-Egr2 in groups. (C) Numerization of (B).

<https://doi.org/10.1371/journal.pone.0177843.g007>




Fig 8. The expression of miR-20a/LncRNA-AF113014/Egr2 in HCC. The expressions of Egr2, LncRNA-AF113014 and miR-20a in HCC tissues were analyzed with qPCR.

<https://doi.org/10.1371/journal.pone.0177843.g008>

linking of miR-20a/LncRNA-AF113014/Egr2 was checked in six human HCC tissue samples compared with adjacent non-cancerous tissues (Fig 8). These results suggested that AF113014 up-regulated Egr2 expression through interacting with miR-20a.

AF113014 influences tumor growth *in vivo*

We next determined whether AF113014 could inhibit tumor growth *in vivo*. SMMC7721 cells infected with Ad-AF113014 or Ad-GFP were subcutaneously injected in the hip back of nude mice respectively. We found that AF113014 could markedly inhibited tumor growth, compared with the control group (Fig 9A). The expressions of Ki-67 and Egr2 were measured in tumor tissues via immunohistochemistry. Increased Egr2 expression and decreased Ki-67 expression were observed in the Ad-AF113014 group, compared with control (Fig 9B). Meanwhile, proteins in tumor tissues were extracted and analyzed by western blot. Our results




Fig 9. AF113014 influenced tumor growth *in vivo*. (A) Representative tumors formed in Ad-GFP and Ad-AF113014 infected SMMC7721 cells, and the tumor growth curve of each group. * $P < 0.05$, ** $P < 0.01$. (B) Transplanted tumors sections were stained with Egr2 and Ki-67. (C) Western blot analysis of Egr2 expression in transplanted tumors. GAPDH was used as control.

<https://doi.org/10.1371/journal.pone.0177843.g009>

showed that Egr2 expressions in tumor tissues derived from Ad-AF113014 group was higher than that from Ad-GFP group (Fig 9C). Taken together, we concluded that AF113014 could inhibit tumor growth and promote Egr2 expression *in vivo*.

Discussion

HCC is a heterogeneous type of tumor with high malignancy and poor prognosis. The changes of carcinogenic-related genes may play crucial roles in the status of HCC proliferation, metastasis and invasive ability [44]. Recent studies have indicated that the dysregulation of lncRNAs, such as H19, DBH-AS1, HOTTIP, ATB, HULC, is involved in HCC pathogenesis. A growing

body of literature show that the aberrant expressions of lncRNA could contribute to cancer biology [45–49]. Therefore, study on lncRNA can help us with better correct diagnosis and effective treatment of tumors.

Numerous lncRNAs have been discovered by gene chip or next-generation sequencing methods due to the rapid development of high-throughput DNA technology over the years. In this study, we have identified a novel lncRNA AF113014 through microarray, which is aberrantly expressed in human HCC cell lines, compared to normal hepatocytes. Applying gain-of-function and loss-of-function experiments, we identified that overexpressing AF113014 could inhibit proliferation of HCC cells *in vitro*, while the opposite effect was observed when knockdown of AF113014. These results suggest that AF113014 might act as a tumor suppressor in HCC cells. Related studies have shown that lncRNA has been reported to influence the expression of adjacent genes on chromosome to exhibit its biological function. Mechanistic study further found that Egr2 was a downstream target of AF113014. Over-expression of AF113014 promoted Egr2 expression while knockdown of AF113014 decreased the expression of Egr2 both in mRNA and protein levels.

Egr2, a transcription factor with zinc-finger structure, is a member of EGR family. The EGR family can encode immediate-early transcription factors and is composed of four members: EGR1, EGR2, EGR3 and EGR4. EGR family members have been reported to take part in apoptosis regulation. For example, EGR1 has both pro-apoptotic and pro-survival functions depending on the cell lineage [50–52]. EGR2, as a target of the p53 family, could directly affect the apoptotic pathway mediated by p53 family [53]. Plenty of document information included findings that endogenous EGR2 was significantly low expression in various cancer cell lines and primary cancers [54–57]. Egr2 can be induced by a variety of extracellular signal molecules, such as cytokines and kinase, and combine with gene promoters and affect the expression of the downstream genes [58–60]. Evidence showed that dysregulation of Egr2 was found in chronic lymphocytic leukemia and miRNA-150 promoted the proliferation of gastric cancer through negative regulating Egr2 [61, 62]. However, the function of Egr2 in HCC progression was not reported at present. In our study, Egr2 was down-expressed in HCC cell lines and tissues. Besides, over-expression of Egr2 suppressed proliferation of HCC cells both *in vitro* and *in vivo*.

The functional mechanisms of lncRNAs have the following aspects: transcriptional interference, inducing chromatin remodeling and histone modifications, hybridization of sense and antisense RNAs, binding specific protein and being small RNA precursor, etc [63]. It has been proved that lncRNAs and microRNAs could form regulatory networks in order to play their regulatory role by various studies [64–68]. To explore the underlying mechanism of AF113014-induced proliferation inhibition, we hypothesized AF113014 interacted with a certain microRNA which resulting in Egr2 expression changes in HCC. In this study, we found miR-20a could combine with Egr2-3'UTR region and there was also a complementary base pairing relationship between AF113014 and miR20a. Dual-luciferase reporter assay showed that Egr2 was a target gene of miR-20a and AF113014 could weaken the inhibition of miR-20a to Egr2. These results suggested that AF113014 could regulate the expression of Egr2 by interaction with miR-20a.

In summary, our study revealed the functions and mechanism of AF113014, miR-20a and Egr2 in HCC. These data might provide new research ideas for HCC treatment and prognosis.

Supporting information

S1 Fig. Vector construction and transfection. The infection efficiency of Ad-GFP, Ad-AF113014 and Ad-Egr2 were observed under a fluorescence microscope. (TIF)

S2 Fig. The expressions of NRBF2 protein were analyzed with Western blot.
(TIF)

S3 Fig. Website forecasted the miRNAs which can bind with Egr2-3'UTR.
(TIF)

Acknowledgments

This work was supported by the Major National S&T Program (2013ZX10002002, ALH), the major project of Chongqing Science & Technology Commission (cstc2013jcyjC10002, ALH), the Natural Science Foundation Project of CQ CSTC (2010BB5359), the Nature Science Foundation of China (81471946).

Author Contributions

Conceptualization: HT.

Data curation: TZ DW JC.

Formal analysis: JC.

Funding acquisition: AH.

Investigation: DW TZ YT HP LZ.

Methodology: XC.

Project administration: HT AH.

Resources: YT LZ.

Writing – original draft: DW.

Writing – review & editing: JC HT.

References

1. Cao H, Phan H and Yang LX. Improved chemotherapy for hepatocellular carcinoma. *Anticancer Res.* 2012; 32(4):1379–1386. PMID: [22493374](https://pubmed.ncbi.nlm.nih.gov/22493374/)
2. Arzumanyan A, Reis HM and Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. *Nat Rev Cancer.* 2013; 13(2):123–135. <https://doi.org/10.1038/nrc3449> PMID: [23344543](https://pubmed.ncbi.nlm.nih.gov/23344543/)
3. Jia S and Cai J. Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer. *Anticancer Res.* 2016; 36(3):1111–1118. PMID: [26977006](https://pubmed.ncbi.nlm.nih.gov/26977006/)
4. Yiu AJ and Yiu CY. Biomarkers in Colorectal Cancer. *Anticancer Res.* 2016; 36(3):1093–1102. PMID: [26977004](https://pubmed.ncbi.nlm.nih.gov/26977004/)
5. Cameron SJ, Lewis KE, Beckmann M, Allison GG, Ghosal R, Lewis PD, et al. The metabolomic detection of lung cancer biomarkers in sputum. *Lung Cancer.* 2016; 94:88–95. <https://doi.org/10.1016/j.lungcan.2016.02.006> PMID: [26973212](https://pubmed.ncbi.nlm.nih.gov/26973212/)
6. Lin Z, Hu Y, Lai S, Xue M, Lin J, Qian Y, et al. Long Noncoding RNA: its partners and their roles in cancer. *Neoplasma.* 2015; 62(6):846–854. https://doi.org/10.4149/neo_2015_103 PMID: [26458323](https://pubmed.ncbi.nlm.nih.gov/26458323/)
7. Gutschner T and Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. *RNA Biol.* 2012; 9(6):703–719. <https://doi.org/10.4161/ma.20481> PMID: [22664915](https://pubmed.ncbi.nlm.nih.gov/22664915/)
8. Chu C, Qu K, Zhong FL, Artandi SE and Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. *Mol Cell.* 2011; 44(4):667–678. <https://doi.org/10.1016/j.molcel.2011.08.027> PMID: [21963238](https://pubmed.ncbi.nlm.nih.gov/21963238/)
9. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet.* 2011; 43(7):621–629. <https://doi.org/10.1038/ng.848> PMID: [21642992](https://pubmed.ncbi.nlm.nih.gov/21642992/)

10. Dinger ME, Pang KC, Mercer TR and Mattick JS. Differentiating protein-coding and noncoding RNA: challenges and ambiguities. *PLoS Comput Biol.* 2008; 4(11):e1000176. <https://doi.org/10.1371/journal.pcbi.1000176> PMID: 19043537
11. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature.* 2009; 458(7235):223–227. <https://doi.org/10.1038/nature07672> PMID: 19182780
12. Sun M and Kraus WL. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. *Endocr Rev.* 2015; 36(1):25–64. <https://doi.org/10.1210/er.2014-1034> PMID: 25426780
13. Su YJ, Yu J, Huang YQ and Yang J. Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer. *Int J Mol Sci.* 2015; 16(6):13322–13338. <https://doi.org/10.3390/ijms160613322> PMID: 26110379
14. Tycowski KT, Guo YE, Lee N, Moss WN, Vallery TK, Xie M, et al. Viral noncoding RNAs: more surprises. *Genes Dev.* 2015; 29(6):567–584. <https://doi.org/10.1101/gad.259077.115> PMID: 25792595
15. Patil VS, Zhou R and Rana TM. Gene regulation by non-coding RNAs. *Crit Rev Biochem Mol Biol.* 2014; 49(1):16–32. <https://doi.org/10.3109/10409238.2013.844092> PMID: 24164576
16. Zhang L, Yang F, Yuan JH, Yuan SX, Zhou WP, Huo XS, et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. *Carcinogenesis.* 2013; 34(3):577–586. <https://doi.org/10.1093/carcin/bgs381> PMID: 23222811
17. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. *Cancer Res.* 2006; 66(10):5330–5337. <https://doi.org/10.1158/0008-5472.CAN-06-0037> PMID: 16707459
18. Yoshimizu T, Miroglio A, Ripoché MA, Gabory A, Vernucci M, Riccio A, et al. The H19 locus acts in vivo as a tumor suppressor. *Proc Natl Acad Sci U S A.* 2008; 105(34):12417–12422. <https://doi.org/10.1073/pnas.0801540105> PMID: 18719115
19. Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. *Hepatology.* 2011; 54(5):1679–1689. <https://doi.org/10.1002/hep.24563> PMID: 21769904
20. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature.* 2010; 464(7291):1071–1076. <https://doi.org/10.1038/nature08975> PMID: 20393566
21. Tsai MC, Manor O, Wan Y, Mosammamaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. *Science.* 2010; 329(5992):689–693. <https://doi.org/10.1126/science.1192002> PMID: 20616235
22. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell.* 2011; 147(2):358–369. <https://doi.org/10.1016/j.cell.2011.09.028> PMID: 22000014
23. Mattick JS. Linc-ing Long noncoding RNAs and enhancer function. *Dev Cell.* 2010; 19(4):485–486. <https://doi.org/10.1016/j.devcel.2010.10.003> PMID: 20951339
24. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. *Nature.* 2008; 454(7200):126–130. <https://doi.org/10.1038/nature06992> PMID: 18509338
25. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. *Oncogene.* 2011; 30(47):4750–4756. <https://doi.org/10.1038/onc.2011.193> PMID: 21625215
26. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods.* 2001; 25(4):402–408. <https://doi.org/10.1006/meth.2001.1262> PMID: 11846609
27. Cao Y, Wang Y, Abi Saab WF, Yang F, Pessin JE and Backer JM. NRBF2 regulates macroautophagy as a component of Vps34 Complex I. *Biochem J.* 2014; 461(2):315–322. <https://doi.org/10.1042/BJ20140515> PMID: 24785657
28. Zhong Y, Morris DH, Jin L, Patel MS, Karunakaran SK, Fu YJ, et al. Nrnf2 protein suppresses autophagy by modulating Atg14L protein-containing Beclin 1-Vps34 complex architecture and reducing intracellular phosphatidylinositol-3 phosphate levels. *J Biol Chem.* 2014; 289(38):26021–26037. <https://doi.org/10.1074/jbc.M114.561134> PMID: 25086043
29. Yasumo H, Masuda N, Furusawa T, Tsukamoto T, Sadano H and Osumi T. Nuclear receptor binding factor-2 (NRBF-2), a possible gene activator protein interacting with nuclear hormone receptors. *Biochim Biophys Acta.* 2000; 1490(1–2):189–197. PMID: 10786636

30. Gabet Y, Baniwal SK, Leclerc N, Shi Y, Kohn-Gabet AE, Cogan J, et al. Krox20/EGR2 deficiency accelerates cell growth and differentiation in the monocytic lineage and decreases bone mass. *Blood*. 2010; 116(19):3964–3971. <https://doi.org/10.1182/blood-2010-01-263830> PMID: 20716776
31. Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, et al. The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-beta that is up-regulated in systemic sclerosis and mediates profibrotic responses. *Am J Pathol*. 2011; 178(5):2077–2090. <https://doi.org/10.1016/j.ajpath.2011.01.035> PMID: 21514423
32. Grunewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nat Genet*. 2015; 47(9):1073–1078. <https://doi.org/10.1038/ng.3363> PMID: 26214589
33. Ogbe A, Miao T, Symonds AL, Omodho B, Singh R, Bhullar P, et al. Early Growth Response Genes 2 and 3 Regulate the Expression of Bcl6 and Differentiation of T Follicular Helper Cells. *J Biol Chem*. 2015; 290(33):20455–20465. <https://doi.org/10.1074/jbc.M114.634816> PMID: 25979336
34. Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, et al. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. *J Immunol*. 2015; 194(3):960–972. <https://doi.org/10.4049/jimmunol.1402143> PMID: 25548232
35. Zhang M, Wang Y, Wang JS, Liu J, Liu MM and Yang HB. The roles of Egr-2 in autoimmune diseases. *Inflammation*. 2015; 38(3):972–977. <https://doi.org/10.1007/s10753-014-0059-z> PMID: 25381473
36. Chandra A, Lan S, Zhu J, Siclari VA and Qin L. Epidermal growth factor receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing early growth response 2 (EGR2) expression. *J Biol Chem*. 2013; 288(28):20488–20498. <https://doi.org/10.1074/jbc.M112.447250> PMID: 23720781
37. Tan JY and Marques AC. miRNA-mediated crosstalk between transcripts: The missing "linc"? *Bioessays*. 2016; 38(3):295–301. <https://doi.org/10.1002/bies.201500148> PMID: 26835602
38. Xin W, Liu X, Ding J, Zhao J, Zhou Y, Wu Q, et al. Long non-coding RNA derived miR-205-5p modulates human endometrial cancer by targeting PTEN. *Am J Transl Res*. 2015; 7(11):2433–2441. PMID: 26807189
39. Paraskevopoulou MD and Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. *Methods Mol Biol*. 2016; 1402:271–286. https://doi.org/10.1007/978-1-4939-3378-5_21 PMID: 26721498
40. Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L, et al. MiRNA-192 [corrected] and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. *PLoS Genet*. 2015; 11(12):e1005726. <https://doi.org/10.1371/journal.pgen.1005726> PMID: 26710269
41. Wang J, Lei ZJ, Guo Y, Wang T, Qin ZY, Xiao HL, et al. miRNA-regulated delivery of lincRNA-p21 suppresses beta-catenin signaling and tumorigenicity of colorectal cancer stem cells. *Oncotarget*. 2015; 6(35):37852–37870. <https://doi.org/10.18632/oncotarget.5635> PMID: 26497997
42. Zhuo W, Ge W, Meng G, Jia S, Zhou X and Liu J. MicroRNA20a promotes the proliferation and cell cycle of human osteosarcoma cells by suppressing early growth response 2 expression. *Mol Med Rep*. 2015; 12(4):4989–4994. <https://doi.org/10.3892/mmr.2015.4098> PMID: 26238942
43. Li X, Zhang Z, Yu M, Li L, Du G, Xiao W, et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). *Int J Mol Sci*. 2013; 14(8):16226–16239. <https://doi.org/10.3390/ijms140816226> PMID: 23924943
44. Bruix J, Gores GJ and Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. *Gut*. 2014; 63(5):844–855. <https://doi.org/10.1136/gutjnl-2013-306627> PMID: 24531850
45. Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, et al. Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. *J Cachexia Sarcopenia Muscle*. 2016.
46. Huang JL, Ren TY, Cao SW, Zheng SH, Hu XM, Hu YW, et al. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. *Oncotarget*. 2015; 6(32):33791–33804. <https://doi.org/10.18632/oncotarget.5667> PMID: 26393879
47. Chang S, Liu J, Guo S, He S, Qiu G, Lu J, et al. HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression. *Oncol Rep*. 2016; 35(6):3577–3585. <https://doi.org/10.3892/or.2016.4743> PMID: 27108607
48. Ma CC, Xiong Z, Zhu GN, Wang C, Zong G, Wang HL, et al. Long non-coding RNA ATB promotes glioma malignancy by negatively regulating miR-200a. *J Exp Clin Cancer Res*. 2016; 35(1):90. <https://doi.org/10.1186/s13046-016-0367-2> PMID: 27267902
49. Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. *Oncotarget*. 2016.

50. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. *Cell*. 2006; 126(4):755–766. <https://doi.org/10.1016/j.cell.2006.06.052> PMID: 16923394
51. Droin NM, Pinkoski MJ, Dejardin E and Green DR. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. *Mol Cell Biol*. 2003; 23(21):7638–7647. <https://doi.org/10.1128/MCB.23.21.7638-7647.2003> PMID: 14560009
52. O'Donovan KJ, Tourtellotte WG, Millbrandt J and Baraban JM. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. *Trends Neurosci*. 1999; 22(4):167–173. PMID: 10203854
53. Yokota I, Sasaki Y, Kashima L, Idogawa M and Tokino T. Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene. *Int J Oncol*. 2010; 37(6):1407–1416. PMID: 21042708
54. Unoki M and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. *Oncogene*. 2001; 20(33):4457–4465. <https://doi.org/10.1038/sj.onc.1204608> PMID: 11494141
55. Unoki M and Nakamura Y. Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity. *FEBS Lett*. 2003; 554(1–2):67–72. PMID: 14596916
56. Yin P, Navarro A, Fang F, Xie A, Coon JS, Richardson C, et al. Early growth response-2 expression in uterine leiomyoma cells: regulation and function. *Fertil Steril*. 2011; 96(2):439–444. <https://doi.org/10.1016/j.fertnstert.2011.05.062> PMID: 21703609
57. To SQ, Simpson ER, Knower KC and Clyne CD. Involvement of early growth response factors in TNF α -induced aromatase expression in breast adipose. *Breast Cancer Res Treat*. 2013; 138(1):193–203. <https://doi.org/10.1007/s10549-013-2413-5> PMID: 23338760
58. Nafez S, Oikawa K, Odero GL, Sproule M, Ge N, Schapansky J, et al. Early growth response 2 (Egr-2) expression is triggered by NF-kappaB activation. *Mol Cell Neurosci*. 2015; 64:95–103. <https://doi.org/10.1016/j.mcn.2014.12.008> PMID: 25553923
59. Doncel-Perez E, Mateos-Hernandez L, Pareja E, Garcia-Forcada A, Villar M, Tobes R, et al. Expression of Early Growth Response Gene-2 and Regulated Cytokines Correlates with Recovery from Guillain-Barre Syndrome. *J Immunol*. 2016; 196(3):1102–1107. <https://doi.org/10.4049/jimmunol.1502100> PMID: 26718337
60. Burns FR, Lanham KA, Xiong KM, Gooding AJ, Peterson RE and Heideman W. Analysis of the zebrafish sox9b promoter: Identification of elements that recapitulate organ-specific expression of sox9b. *Gene*. 2016; 578(2):281–289. <https://doi.org/10.1016/j.gene.2015.12.041> PMID: 26721460
61. Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, et al. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. *Biochem Biophys Res Commun*. 2010; 392(3):340–345. <https://doi.org/10.1016/j.bbrc.2009.12.182> PMID: 20067763
62. Jiang Y and Elemento O. Tracing the roots of cancer evolution. *Cancer Discov*. 2014; 4(9):995–997. <https://doi.org/10.1158/2159-8290.CD-14-0743> PMID: 25185189
63. Wang KC and Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell*. 2011; 43(6):904–914. <https://doi.org/10.1016/j.molcel.2011.08.018> PMID: 21925379
64. Zhou X, Ji G, Ke X, Gu H, Jin W and Zhang G. MiR-141 Inhibits Gastric Cancer Proliferation by Interacting with Long Noncoding RNA MEG3 and Down-Regulating E2F3 Expression. *Dig Dis Sci*. 2015; 60(11):3271–3282. <https://doi.org/10.1007/s10620-015-3782-x> PMID: 26233544
65. Hunten S, Kaller M, Drepper F, Oeljeklaus S, Bonfert T, Erhard F, et al. p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses. *Mol Cell Proteomics*. 2015; 14(10):2609–2629. <https://doi.org/10.1074/mcp.M115.050237> PMID: 26183718
66. Liu YW, Sun M, Xia R, Zhang EB, Liu XH, Zhang ZH, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. *Cell Death Dis*. 2015; 6:e1802. <https://doi.org/10.1038/cddis.2015.150> PMID: 26136075
67. Cai H, Xue Y, Wang P, Wang Z, Li Z, Hu Y, et al. The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. *Oncotarget*. 2015; 6(23):19759–19779. <https://doi.org/10.18632/oncotarget.4331> PMID: 26078353
68. Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. *Oncotarget*. 2015; 6(26):22513–22525. <https://doi.org/10.18632/oncotarget.4154> PMID: 26068968

© 2017 Zeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License:

<http://creativecommons.org/licenses/by/4.0/> (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.